Literature DB >> 6803189

Fabry disease: impaired autonomic function.

W J Cable, E H Kolodny, R D Adams.   

Abstract

Previous reports of extensive lipid accumulation within neurons of the autonomic nervous system in Fabry disease suggest an anatomicopathologic basis for the peculiar pain, diminished sweating, and gastrointestinal symptoms experienced in this disorder. To further assess autonomic function in Fabry disease, noninvasive clinical tests were performed on 10 patients. Diminished sweating was found in each; the loss was approximately uniform proximally and distally, suggesting sweat gland dysfunction rather than autonomic neuropathy. Impaired pupillary constriction with pilocarpine, and reduced saliva and tear formation were found in half the patients. Disordered intestinal mobility was demonstrated in the oldest patients. In all cases, the cutaneous flare response to scratch and intradermal histamine was diminished, and pruritus was not experienced. Signs of autonomic dysfunction are present in Fabry disease and correlate with the known lipid deposition in autonomic neurons.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803189     DOI: 10.1212/wnl.32.5.498

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Authors:  L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Journal:  J Inherit Metab Dis       Date:  2006-07-27       Impact factor: 4.982

Review 2.  Autonomic involvement in inherited neuropathies.

Authors:  P K Thomas
Journal:  Clin Auton Res       Date:  1992-02       Impact factor: 4.435

3.  [Fabry's disease: new therapeutic options for this lysosomal storage disorder].

Authors:  A J Grau; M Schwaninger; H H Goebel; M Beck
Journal:  Nervenarzt       Date:  2003-05-20       Impact factor: 1.214

4.  Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.

Authors:  Chloe Tesmoingt; Olivier Lidove; Axele Reberga; Marguerite Thetis; Chloe Ackaert; Pascale Nicaise; Philippe Arnaud; Thomas Papo
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

5.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

6.  [Axon-reflex based nerve fiber function assessment in the detection of autonomic neuropathy].

Authors:  T Siepmann; B M-W Illigens; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

7.  Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

Authors:  Raphael Schiffmann; Hasan Askari; Margaret Timmons; Chevalia Robinson; William Benko; Roscoe O Brady; Markus Ries
Journal:  J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 10.121

8.  Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Wouter Wieling; Frits A Wijburg; Carla E M Hollak
Journal:  BMC Neurol       Date:  2010-06-07       Impact factor: 2.474

Review 9.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

10.  Increased globotriaosylceramide in familial dysautonomia.

Authors:  P Strasberg; H Yeger; I Warren
Journal:  Lipids       Date:  1992-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.